Oncology Institute, Inc. TOI
We take great care to ensure that the data presented and summarized in this overview for Oncology Institute, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TOI
View all-
Deerfield Management Company, L.P. (Series C) New York, NY3.36MShares$3.23 Million0.03% of portfolio
-
Tiff Advisory Services Inc2.98MShares$2.86 Million0.3% of portfolio
-
Cincinnati Insurance CO2.03MShares$1.95 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$1.68 Million0.0% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.75MShares$1.68 Million0.37% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.73MShares$1.66 Million0.0% of portfolio
-
Free Gulliver LLC New Orleans, LA601KShares$576,7170.09% of portfolio
-
Geode Capital Management, LLC Boston, MA347KShares$333,4530.0% of portfolio
-
Four World Capital Management LLC New York, NY257KShares$246,7200.04% of portfolio
-
Parian Global Management LP Pound Ridge, NY241KShares$231,0953.63% of portfolio
Latest Institutional Activity in TOI
Top Purchases
Top Sells
About TOI
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Insider Transactions at TOI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
258
-0.81%
|
$0
$0.34 P/Share
|
|
Dec 03
2024
|
Jeremy Castle Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,130
-1.37%
|
$0
$0.16 P/Share
|
|
Dec 02
2024
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
50,000
+6.98%
|
$0
$0.15 P/Share
|
|
Nov 26
2024
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
250,000
+28.84%
|
$0
$0.17 P/Share
|
|
Nov 22
2024
|
Richard A Barasch Director |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+16.09%
|
-
|
|
Nov 22
2024
|
Mark L Pacala Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+27.11%
|
-
|
|
Nov 22
2024
|
Karen Marie Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,000
+23.72%
|
-
|
|
Nov 22
2024
|
Anne Mc George Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,000
+23.4%
|
-
|
|
Nov 22
2024
|
Gabriel Ling Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+26.84%
|
-
|
|
Nov 22
2024
|
Mohit Kaushal Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,000
+24.01%
|
-
|
|
Nov 22
2024
|
Brad Hively Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+5.76%
|
-
|
|
Nov 20
2024
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,002
-1.33%
|
$0
$0.14 P/Share
|
|
Nov 20
2024
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
235
-0.73%
|
$0
$0.14 P/Share
|
|
Nov 20
2024
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,727
-0.68%
|
$0
$0.14 P/Share
|
|
Nov 12
2024
|
Brad Hively Director |
SELL
Other acquisition or disposition
|
Direct |
353,450
-49.08%
|
-
|
|
Nov 12
2024
|
Yale Podnos Chief Medical Officer |
SELL
Other acquisition or disposition
|
Direct |
28,398
-14.6%
|
-
|
|
Nov 12
2024
|
Daniel Virnich Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
195,236
-11.24%
|
-
|
|
Nov 12
2024
|
Mark L Pacala Director |
SELL
Other acquisition or disposition
|
Direct |
50,620
-20.73%
|
-
|
|
Aug 16
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
16,333,241
-74.63%
|
-
|
|
Jun 17
2024
|
Brad Hively Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,121
-2.61%
|
$0
$0.46 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 816K shares |
|---|---|
| Open market or private purchase | 300K shares |
| Other acquisition or disposition | 17M shares |
|---|---|
| Sale (or disposition) back to the issuer | 63.2K shares |